PRT-064040 nasal spray for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Dec 2025: Trial registered, NCT07304518
  2. 26 Jan 2026: Trial started, NCT07304518

The trials

NCT07304518: Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

State
Under way
Phase
Phase 2
People
456 planned
Started
26 Jan 2026
Primary completion
Sep 2026
Arms
PRT-064040 nasal spray (dose 1), PRT-064040 nasal spray (dose 2), PRT-064040 nasal spray (dose 3)
Results
None posted
  1. 26 Dec 2025: Trial registered
  2. 26 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.